Fluocinonide
|
Systematic (IUPAC) name |
6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate |
Clinical data |
Trade names |
Lidex |
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
MedlinePlus |
a601054 |
Pregnancy cat. |
|
Legal status |
- AU: Prescription Only (S4)
- UK: POM
- US: ℞-only
|
Routes |
topical |
Pharmacokinetic data |
Metabolism |
hepatic |
Identifiers |
CAS number |
356-12-7 Y |
ATC code |
C05AA11 D07AC08 |
PubChem |
CID 9642 |
DrugBank |
DB01047 |
ChemSpider |
9265 Y |
UNII |
2W4A77YPAN Y |
KEGG |
D00325 Y |
ChEMBL |
CHEMBL1501 Y |
Chemical data |
Formula |
C26H32F2O7 |
Mol. mass |
494.525 g/mol |
SMILES
- O=C(OCC(=O)[C@]45OC(O[C@@H]5C[C@@H]2[C@@]4(C[C@H](O)[C@]3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H](F)C[C@@H]23)C)C)(C)C)C
|
InChI
-
InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 Y
Key:WJOHZNCJWYWUJD-IUGZLZTKSA-N Y
|
Y (what is this?) (verify) |
Fluocinonide (Fluonex, Lidex, Lidex-E, Lonide, Lyderm, and Vanos)[1] is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.
The usual prescription concentration is 0.05% as a topical cream, ointment, or gel. The application area should normally not be covered after application. In certain cases, the physician may recommend the use of an occlusive dressing after application to increase the rate and depth of absorption. The frequency of application depends on the condition being treated and the area affected, but most often it should be applied 2 to 4 times a day.[2]
Fluocinonide ranks as a "high-potency" (second-highest rank) topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects.[medical citation needed]. Fluocinonide should not be used more than two times a day, though usually one application per day is sufficient [3]
Fluocinonide should not be used if infection is present. It should not be applied to the eyes or to sensitive areas such as the genitals or anus.[medical citation needed]
A common potential adverse effect is skin atrophy (thinning of the skin). Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis (HPA) suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Fluocinonide should be used with caution when treating children, pregnant women, nursing mothers, and anyone using the medication for longer than two weeks.
Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs.[4] Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.[5]
References
- ^ MedlinePlus Drug Information: Fluocinonide Topical
- ^ "Fluocinonide Topical". MedlinePlus. US National Library of Medicine, NIH. Retrieved 6 March 2014.
- ^ Template:BNF 64, British National Formulary, September 2012
- ^ Dog Allergies www.squidoo.com/dogallergy
- ^ Zenoble RD, Kemppainen RJ . (1987-09-15). "Adrenocortical suppression by topically applied corticosteroids in healthy dogs". J Am Vet Med Assoc 191 (6): 685–8. PMID 2824410.
Vasoprotectives (C05)
|
|
Antihemorrhoidals for topical use |
corticosteroids |
- Hydrocortisone
- Prednisolone
- Betamethasone
- Fluorometholone
- Fluocortolone
- Dexamethasone
- Fluocinolone acetonide
- Fluocinonide
|
|
local anesthetics |
- Lidocaine
- Tetracaine
- Benzocaine
- Dibucaine
- Procaine
- Oxetacaine
- Pramocaine
|
|
other |
|
|
|
Antivaricose therapy |
heparins or heparinoids for topical use |
- Organo-heparinoid
- Sodium apolate
- Heparin
- Pentosan polysulfate
|
|
sclerosing agents for local injection |
- Monoethanolamine oleate
- Polidocanol
- Inverted sugar syrup
- Sodium tetradecyl sulfate
- Phenol
|
|
other |
|
|
|
Capillary stabilising agents |
bioflavonoids |
- Rutoside
- Monoxerutin
- Diosmin
- Troxerutin
- Hidrosmin
|
|
other |
|
|
|
|
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug (C2s+n/3/4/5/7/8/9)
|
|
|
|
Corticosteroids – glucocorticoids and mineralocorticoids (H02)
(also A07EA, C05AA, D07, D10AA, R01AD, R03BA, S01BA, S02B, and S03B)
|
|
Mineralocorticoids
(3-one, 4-ene,
no FG at 16) |
- Pregnenedione: ALDOSTERONE
- 11-DEOXYCORTICOSTERONE
- HALOGENATED AT 9: Fludrocortisone
|
|
Glucocorticoids
(3-one, 4-ene,
11-FG,
17-hydroxy) |
Pregnene
|
|
|
Pregnenedione
(+20-one)
|
- HYDROCORTISONE/CORTISOL# (Hydrocortisone aceponate
- Hydrocortisone buteprate
- Hydrocortisone butyrate)
- Budesonide
- Ciclesonide
- Deflazacort
- Medrysone
- Tixocortol
- HALOGENATED AT 6: Cloprednol
- HALOGENATED, WITH FG AT 16: Halcinonide
|
|
Pregnadiene (+1-ene)
|
- Rimexolone
- HALOGENATED, WITH FG AT 16: Flunisolide
- Triamcinolone
- Amcinonide
- Fluocinolone acetonide (Fluocinonide)
|
|
Pregnadienediol
(+21-hydroxy)
|
- Prednisone (Meprednisone)
- HALOGENATED AT 9: Fluorometholone
- HALOGENATED, WITH FG AT 16: Fluocortolone (Clocortolone
- Diflucortolone
- Fluocortin)
- Desoximetasone
|
|
Pregnadienetriol
(+11-hydroxy)
|
- Prednisolone# (Methylprednisolone
- Methylprednisolone aceponate
- Prednicarbate
- Prednylidene)
- Desonide
- HALOGENATED: Fluprednisolone (Difluprednate
- Fluperolone)
- HALOGENATED, WITH FG AT 16: Dexamethasone#
- Betamethasone (Clobetasol
- Clobetasone
- Diflorasone
- Halometasone
- Ulobetasol)
- Beclometasone
- Paramethasone
- Alclometasone
- Fluclorolone acetonide
- Flumetasone
- Fluprednidene
|
|
Pregnatriene
(+2-ene)
|
|
|
Androstene
|
- HALOGENATED, WITH FG AT 16: Fluticasone (Fluticasone propionate
- Fluticasone furoate)
|
|
Other/ungrouped
|
- HALOGENATED: Loteprednol
- HALOGENATED, WITH FG AT 16: Fludroxycortide
- Formocortal
- Mometasone furoate
|
|
|
Aldosterone antagonists |
- Spironolactone
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
Synthesis modifiers |
- Trilostane
- Carbenoxolone
- Aminoglutethimide
- Metyrapone
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
|
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|